About Axol Bioscience
Axol Bioscience develops human induced pluripotent stem cell (iPSC) technologies for disease research and preclinical drug discovery. The company specialises in the manufacture of iPSC-derived cells and the provision of laboratory services that support the development of physiologically relevant in vitro models. Its expertise spans iPSC reprogramming, gene editing, cell differentiation, banking and quality control. Axol supports research in neuroscience, neuroinflammation, ophthalmology, dermatology and cardiovascular biology, including studies of neurodegenerative disorders such as Alzheimer’s, Parkinson’s, Huntington’s disease and ALS. Its platforms enable researchers to investigate disease mechanisms, evaluate therapeutic candidates and improve the translational relevance of cell-based models.
The company’s portfolio includes cryopreserved human iPSC-derived cells, patient-derived iPSC lines, retinal organoids and custom model development services. Axol also provides assay development, compound testing, sequencing, genome editing and contract cell manufacturing for research and drug discovery programmes. Product families such as the axoCells™ range are designed for use in monoculture, co-culture, organ-on-chip and other advanced in vitro systems. These tools support target validation, safety assessment, toxicity testing and efficacy studies across multiple therapeutic areas.
Europa Biosite’s subsidiaries distribute for Axol Bioscience in Switzerland.